Skip to main content
vTv Therapeutics Inc. logo

vTv Therapeutics Inc. — Investor Relations & Filings

Ticker · VTVT ISIN · US9183852048 LEI · 549300WQE5EI9R35SE66 US Manufacturing
Filings indexed 577 across all filing types
Latest filing 2026-05-13 Share Issue/Capital Cha…
Country US United States of America
Listing US VTVT

About vTv Therapeutics Inc.

https://vtvtherapeutics.com/

vTv Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. The company's primary commitment is to improving the lives of patients with diabetes. Its lead clinical drug candidate is cadisegliatin, a potential adjunctive therapy to insulin for the treatment of type 1 diabetes. In collaboration with development partners, vTv is also pursuing additional indications for its pipeline molecules, including type 2 diabetes and other chronic conditions.

Recent filings

Filing Released Lang Actions
424B2 - vTv Therapeutics Inc. (0001641489) (Filer)
Share Issue/Capital Change Classification · 91% confidence The document is a Form 424B2 prospectus supplement relating to an at-the-market equity offering of Class A common stock (up to $47.5 million), detailing the terms of the sale agreement, use of proceeds, dilution and plan of distribution. This is not an annual or quarterly report, management discussion, proxy, merger, or earnings release. It is an offering document announcing a new share issuance to raise capital. Therefore, it should be classified under Share Issue/Capital Change (SHA).
2026-05-13 English
8-K - vTv Therapeutics Inc. (0001641489) (Filer)
Regulatory Filings
2026-05-13 English
S-8 - vTv Therapeutics Inc. (0001641489) (Filer)
Regulatory Filings
2026-05-13 English
10-Q - vTv Therapeutics Inc. (0001641489) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-13 English
8-K - VTV THERAPEUTICS INC. (0001641489) (Filer)
Investor Presentation Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 26, 2026. It specifically mentions that it includes an updated slide presentation attached as Exhibit 99.1, described as an "Investor Presentation." The text states that the presentation is used in meetings with investors and analysts and may be updated over time. The document does not contain detailed financial statements or comprehensive financial analysis but rather a presentation for investors. The document length is 3783 characters, which is relatively short and consistent with a presentation filing rather than a full report. Therefore, this filing is best classified as an Investor Presentation (IP).
2026-02-26 English
4 - VTV THERAPEUTICS INC. (0001641489) (Filer)
Director's Dealing
2026-02-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.